Pankreatitis Kronis

01Pathophysiology

Chronic pancreatitis results from repeated episodes of pancreatic injury that trigger an irreversible cycle of inflammation, necrosis, and fibrosis. The most widely accepted model is the sentinel acute pancreatitis event (SAPE) hypothesis, which proposes that an initial insult (most commonly alcohol or its toxic metabolites) activates pancreatic stellate cells. These stellate cells, once activated, produce collagen and extracellular matrix, driving progressive fibrosis that replaces normal pancreatic tissue. Unlike acute pancreatitis, where the gland can recover, chronic pancreatitis represents a point of no return.

Alcohol contributes through multiple mechanisms. Ethanol is metabolized within acinar cells to acetaldehyde and fatty acid ethyl esters, both of which are directly toxic. These metabolites destabilize zymogen granules and cause premature intracellular activation of trypsinogen to trypsin, which then activates other digestive enzymes. Simultaneously, alcohol increases the protein concentration of pancreatic secretions while reducing bicarbonate output, leading to the formation of protein plugs within the ductal system. Over time, these plugs calcify, producing the hallmark pancreatic calcifications (ductal stones) visible on imaging. Tobacco smoking independently accelerates this process and is now recognized as an independent risk factor that compounds the damage from alcohol.

The downstream consequences of fibrosis are twofold. First, destruction of acinar cells leads to exocrine insufficiency. Because the pancreas has tremendous functional reserve, clinically apparent fat maldigestion (steatorrhea) does not develop until more than 90% of exocrine function is lost. This is why patients may have chronic pancreatitis for years before steatorrhea becomes obvious. Second, progressive loss of islet cells leads to endocrine insufficiency, producing a form of diabetes classified as type 3c (pancreatogenic diabetes). This form of diabetes is characterized by deficiency of both insulin and glucagon, which makes patients particularly susceptible to hypoglycemia during treatment.

Pain in chronic pancreatitis is multifactorial. It arises from increased intraductal pressure due to strictures and stones, pancreatic ischemia from fibrosis compressing the microvasculature, and direct neural inflammation and fibrosis of intrapancreatic nerves. Inflammatory infiltrates surrounding nerves cause upregulation of pain mediators, explaining why the pain can persist even after the gland becomes atrophic and "burnt out."

02Classification and Clinical Manifestation

The TIGAR-O classification system organizes the etiologies of chronic pancreatitis:

Morphologically, chronic pancreatitis is further divided based on ductal anatomy, which guides treatment decisions:

Clinical manifestations evolve through stages:

03Diagnostic Workup

When a vignette describes a patient with chronic epigastric pain, weight loss, and a long history of alcohol use, the best initial test is CT of the abdomen. The finding of pancreatic calcifications on CT is essentially diagnostic and is the single most recognizable imaging finding on an exam. If CT shows calcifications, you can stop there for the structural diagnosis.

However, CT has poor sensitivity for early chronic pancreatitis before calcifications and gross structural changes develop. In this setting, when the clinical suspicion remains high but CT is unremarkable, the next step is endoscopic ultrasound (EUS), which is the most sensitive imaging modality for detecting early parenchymal and ductal changes. Secretin-stimulated MRCP is a reasonable noninvasive alternative.

To evaluate the functional consequences, order fecal elastase-1 as the best initial test for exocrine insufficiency. It is a simple stool test that is not affected by concurrent pancreatic enzyme replacement therapy, making it practical for both diagnosis and monitoring. The 72-hour fecal fat collection is more cumbersome but serves as the gold standard for documenting steatorrhea.

A critical teaching point: do not be tricked by normal amylase and lipase levels in a patient with suspected chronic pancreatitis. In advanced disease, the fibrosed and atrophic gland simply cannot produce enough enzymes to elevate serum levels. Normal enzyme levels do not rule out the diagnosis.

04Management and Treatment

Acute stabilization in chronic pancreatitis centers on managing pain flares. During an acute exacerbation overlying chronic disease, treat as you would acute pancreatitis: IV fluids, nil per os if pain is severe, and analgesia. Avoid NSAIDs long-term due to gastrointestinal risks in a malnourished patient.

For long-term management, alcohol and smoking cessation is the single highest-yield intervention and should be emphasized at every visit. It does not reverse existing fibrosis, but it meaningfully slows the rate of functional decline.

PERT is the cornerstone of treating exocrine insufficiency. The minimum effective dose per meal is lipase 40,000 to 50,000 USP units, divided so that some is taken at the start and the remainder during the meal, ensuring the enzymes mix with the food. If steatorrhea persists despite adequate dosing, add a PPI rather than simply increasing the enzyme dose, because gastric acid is the most common reason for treatment failure. The acid denatures unprotected lipase before it reaches the duodenum.

If pain remains refractory to medical therapy and the patient has a dilated main pancreatic duct (greater than 7 mm), the next best step is lateral pancreaticojejunostomy, which decompresses the duct and provides durable pain relief. For patients with an inflammatory mass in the head of the pancreas, a Whipple procedure is preferred because it also allows histologic exclusion of pancreatic adenocarcinoma, which can be indistinguishable from chronic pancreatitis on imaging.

A key contraindication to remember: in patients with type 3c diabetes, metformin is not the ideal first-line agent. These patients have lost both insulin-producing beta cells and glucagon-producing alpha cells. The loss of the glucagon counter-regulatory response makes them highly prone to hypoglycemia, so insulin is the preferred treatment, with careful dose titration.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common trap with chronic pancreatitis questions is the student who sees normal amylase and lipase and immediately rules out a pancreatic diagnosis. Exam writers exploit this predictable reflex. In chronic pancreatitis, the gland is fibrosed and atrophic, often incapable of producing enough enzymes to raise serum levels. A "burnt-out" pancreas is still a diseased pancreas.

A second frequent pitfall involves steatorrhea. Students often associate any degree of pancreatic damage with fat malabsorption, but steatorrhea requires loss of more than 90% of exocrine function. A vignette describing early chronic pancreatitis with pain but no steatorrhea is entirely consistent with the diagnosis and should not steer you away from it.

The third trap involves the overlap between chronic pancreatitis and pancreatic cancer. When a vignette presents an older patient with a pancreatic head mass, new-onset diabetes, and weight loss, the test is checking whether you recognize that these two conditions can be indistinguishable on imaging alone. The correct next step is tissue sampling (EUS-guided fine needle aspiration), not empiric treatment for either condition.

Finally, remember the diabetes subtype. Type 3c pancreatogenic diabetes is not the same as type 2 diabetes. These patients lack glucagon in addition to insulin. Treating them with sulfonylureas or aggressive insulin regimens without accounting for this absent counter-regulatory hormone leads to severe hypoglycemia. The core competency being tested across chronic pancreatitis questions is your ability to connect irreversible structural damage to its functional consequences and to recognize this diagnosis even when classic laboratory markers are deceptively normal.